Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
The presentation of Biogen’s hugely complex aducanumab pivotal programme confirms that the US regulator is destined to make another polarising decision.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.